We are live on ! Find out more
LAB icon

Standard BioTools
LAB

79 hedge funds and large institutions have $291M invested in Standard BioTools in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 23

35% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $1.04M

28% more capital invested

Capital invested by funds: $227M → $291M (+$64.3M)

1.46% more ownership

Funds ownership: 97.77% → 99.23% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 84 → 79 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
79
Holders Change
-5
Holders Change %
-5.95%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
34
Reduced
23
Closed
11
Calls
$1.41M
Puts
$1.04M
Net Calls
+$366K
Net Calls Change
+$308K

Top Buyers

1
ECM
Endurant Capital Management
California
+$3.19M
2
PVI
Pura Vida Investments
New York
+$1.6M
3
SSA
Schonfeld Strategic Advisors
New York
+$891K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$866K
5
Renaissance Technologies
Renaissance Technologies
New York
+$585K

Top Sellers

1
O
OrbiMed
New York
-$3.6M
2
Russell Investments Group
Russell Investments Group
United Kingdom
-$863K
3
Jennison Associates
Jennison Associates
New York
-$410K
4
PP
Paloma Partners
Connecticut
-$339K
5
BlackRock
BlackRock
New York
-$276K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCS
1
Levin Capital Strategies
New York
$76.4M -$46.4K -6,531 -0.1%
Primecap Management
2
Primecap Management
California
$43.9M +$455K +64,000 +1%
Neuberger Berman Group
3
Neuberger Berman Group
New York
$34M +$172K +24,186 +0.5%
Russell Investments Group
4
Russell Investments Group
United Kingdom
$32M -$863K -121,465 -3%
BlackRock
5
BlackRock
New York
$14.7M -$276K -38,832 -2%
Vanguard Group
6
Vanguard Group
Pennsylvania
$10.6M +$866K +121,815 +9%
Renaissance Technologies
7
Renaissance Technologies
New York
$8.63M +$585K +82,300 +8%
O
8
OrbiMed
New York
$8.07M -$3.6M -505,899 -32%
State Street
9
State Street
Massachusetts
$4.42M -$21.7K -3,053 -0.5%
ECM
10
Endurant Capital Management
California
$4.21M +$3.19M +448,474 +393%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$3.57M +$355K +49,972 +12%
HVC
12
Healthcare Value Capital
New Jersey
$3.37M – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$3.22M -$29.4K -4,140 -1%
SSA
14
Schonfeld Strategic Advisors
New York
$3.19M +$891K +125,400 +42%
PAM
15
Panagora Asset Management
Massachusetts
$3.14M -$115K -16,141 -4%
Northern Trust
16
Northern Trust
Illinois
$3.04M +$302K +42,518 +12%
Millennium Management
17
Millennium Management
New York
$2.58M +$338K +47,566 +16%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.39M +$365K +51,366 +19%
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$1.83M -$80.7K -11,345 -4%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$1.82M +$360K +50,616 +26%
Two Sigma Investments
21
Two Sigma Investments
New York
$1.73M +$551K +77,549 +51%
PVI
22
Pura Vida Investments
New York
$1.69M +$1.6M +225,000 New
PCM
23
Perkins Capital Management
Minnesota
$1.64M +$352K +49,500 +29%
Fuller & Thaler Asset Management
24
Fuller & Thaler Asset Management
California
$1.63M – – –
AC
25
Alexandria Capital
Virginia
$1.41M – – –
1
2 3 4

LAB Hedge Fund Activity: Q3 2018 in Review

79 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2018, worth a combined $291M — up 28% from $227M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LAB and 6 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 34 added.

The largest buyer was Endurant Capital Management, adding an estimated $3.19M. The largest seller was OrbiMed, cutting an estimated $3.6M.

  • 79 institutional investors held Standard BioTools (LAB) as of Q3 2018, down from 84 in Q2 2018.
  • Funds reported $291M of Standard BioTools stock for Q3 2018, up 28% quarter-over-quarter.
  • 6 funds opened new Standard BioTools positions in Q3 2018 and 11 closed out, a net change of -5 holders.
  • The largest Standard BioTools buyer in Q3 2018 was Endurant Capital Management, an estimated $3.19M added.
  • The largest Standard BioTools seller in Q3 2018 was OrbiMed, an estimated $3.6M sold.

Based on aggregated 13F filings for Q3 2018.